Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31070219 | 1.00 | CYP3A4 (0.35) | CYP3A4MAPK1KDM1AKCNH2KDM1B | |
| SCHEMBL2014602 | 0.81 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL31342136 | 0.81 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL30223191 | 0.79 | HTR2A (0.32) | — | |
| SCHEMBL29414007 | 0.79 | TNF (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL1003501 | 0.79 | TNF (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL4458219 | 0.77 | CYP3A4 (0.41) | CYP3A4MAPK1CYP2A6AHR | |
| SCHEMBL30384989 | 0.77 | NOTUM (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL17711300 | 0.77 | NOTUM (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL2892194 | 0.75 | ALDH1A1 (0.33) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2560973-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133182-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CYP3A4 296/4885MAPK1 2664/4885KDM1A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.